Taysha Gene Therapies Share Holder Equity 2020-2024 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Taysha Gene Therapies share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Taysha Gene Therapies share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19B
Dr Reddy's Laboratories (RDY)	$12B
BridgeBio Pharma (BBIO)	$4.3B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.1B
Supernus Pharmaceuticals (SUPN)	$2B
Personalis (PSNL)	$261M
Assembly Biosciences (ASMB)	$98M
Sol-Gel Technologies (SLGL)	$12M
Evoke Pharma (EVOK)	$7M
Teligent (TLGT)	$0M